Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN. Crowe BA, et al. Among authors: aichinger g. Vaccine. 2010 Dec 16;29(2):166-73. doi: 10.1016/j.vaccine.2010.10.065. Epub 2010 Nov 4. Vaccine. 2010. PMID: 21055500
Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection.
Holzer GW, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, Brunner S, Schmid K, Kistner O, Aaskov JG, Falkner FG, Ehrlich H, Barrett PN, Kreil TR. Holzer GW, et al. Among authors: aichinger g. Vaccine. 2011 May 31;29(24):4132-41. doi: 10.1016/j.vaccine.2011.03.089. Epub 2011 Apr 6. Vaccine. 2011. PMID: 21477673
Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial.
Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Müller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN. Aichinger G, et al. Vaccine. 2011 Nov 21;29(50):9376-84. doi: 10.1016/j.vaccine.2011.09.125. Epub 2011 Oct 12. Vaccine. 2011. PMID: 22001875 Clinical Trial.
Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA, Wilder-Smith A, Pavlova BG, Barrett PN, Oh HM, Hui DS, Yuen KY, Fritsch S, Aichinger G, Loew-Baselli A, van der Velden M, Maritsch F, Kistner O, Ehrlich HJ. Tambyah PA, et al. Among authors: aichinger g. Vaccine. 2012 Jan 5;30(2):329-35. doi: 10.1016/j.vaccine.2011.10.088. Epub 2011 Nov 12. Vaccine. 2012. PMID: 22080174 Clinical Trial.
Clinical development of a Vero cell culture-derived seasonal influenza vaccine.
Ehrlich HJ, Berezuk G, Fritsch S, Aichinger G, Singer J, Portsmouth D, Hart MK, El-Amin W, Kistner O, Barrett PN. Ehrlich HJ, et al. Among authors: aichinger g. Vaccine. 2012 Jun 19;30(29):4377-86. doi: 10.1016/j.vaccine.2011.11.114. Epub 2011 Dec 13. Vaccine. 2012. PMID: 22172502 Clinical Trial.
A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals.
Ehrlich HJ, Singer J, Berezuk G, Fritsch S, Aichinger G, Hart MK, El-Amin W, Portsmouth D, Kistner O, Barrett PN. Ehrlich HJ, et al. Among authors: aichinger g. Clin Infect Dis. 2012 Apr;54(7):946-54. doi: 10.1093/cid/cir959. Epub 2012 Jan 19. Clin Infect Dis. 2012. PMID: 22267715 Free PMC article. Clinical Trial.
Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN. Ehrlich HJ, et al. Among authors: aichinger g. Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061. Epub 2012 Apr 1. Vaccine. 2012. PMID: 22475864 Clinical Trial.
Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV, Aichinger G, Pöllabauer EM, Löw-Baselli A, Fritsch S, Benamara K, Kistner O, Müller M, Zeitlinger M, Kollaritsch H, Vesikari T, Ehrlich HJ, Barrett PN. van der Velden MV, et al. Among authors: aichinger g. Vaccine. 2012 Sep 21;30(43):6127-35. doi: 10.1016/j.vaccine.2012.07.077. Epub 2012 Aug 8. Vaccine. 2012. PMID: 22884662 Clinical Trial.
Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV, Geisberger A, Dvorak T, Portsmouth D, Fritz R, Crowe BA, Herr W, Distler E, Wagner EM, Zeitlinger M, Sauermann R, Stephan C, Ehrlich HJ, Barrett PN, Aichinger G. van der Velden MV, et al. Among authors: aichinger g. Clin Vaccine Immunol. 2014 Jun;21(6):867-76. doi: 10.1128/CVI.00065-14. Epub 2014 Apr 16. Clin Vaccine Immunol. 2014. PMID: 24739978 Free PMC article. Clinical Trial.
72 results